Tau PET Imaging in Opioid Use Disorder
Study Details
Study Description
Brief Summary
The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study.
Group 1: individuals with OUD and a history of at least one opioid-related OD in the past year that required naloxone treatment reversal: OUD/OD+ Group 2: individuals with OUD without a lifetime history of opioid-related OD OUD/OD- Group 3: Healthy controls without a lifetime OUD: HCs PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer [18F]PI-2620. Each subject will have one [18F]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Detailed Description
Participants will undergo approximately 30 minutes of static PET scanning of the brain and body starting approximately 45 minutes post injection of [18F]PI-2620. All images will be corrected for scatter and measured photon attenuation and reconstructed using standard reconstruction techniques. Standardized uptake value ratio (SUVr), the ratio of regional to reference uptake, will be calculated with cerebellum as reference, where NFTs are generally not present in neurodegenerative disorders, hence likely not in OUD.
Subjects in all three groups undergo a brain MRI including a structural MRI functional reactivity to an episodic memory task, and undergo a comprehensive neurocognitive battery.
The investigators will draw up to 20 mL of venous blood prior to injection that will be used to measure peripheral blood markers of phosphorylated tau, inflammation, and ApoE genotyping. The results of these research tests will not be given to the subject, will not be included in the medical record and will not be used in the subject's clinical management.
Additional measures will be collected: measures of substance use and related behaviors, psychological and subjective measures, neurocognitive measures and OUD-related health outcomes for correlation with the imaging results.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tau PET/CT PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer [18F]PI-2620. Each subject will have one [18F]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed. Participants will undergo approximately 30 minutes of static PET scanning of the brain and body starting approximately 45 minutes post injection of [18F]PI-2620. All images will be corrected for scatter and measured photon attenuation and reconstructed using standard reconstruction techniques. Standardized uptake value ratio (SUVr), the ratio of regional to reference uptake, will be calculated with cerebellum as reference, where NFTs are generally not present in neurodegenerative disorders, hence likely not in OUD. Subjects in all three groups undergo a brain MRI including a structural MRI functional reactivity to an episodic memory task, and undergo a comprehensive neurocognitive battery. |
Drug: 18F-PI-2620 PET/CT
PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer [18F]PI-2620. Each subject will have one [18F]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
|
Outcome Measures
Primary Outcome Measures
- Standardized uptake value ratio (SUVr), [8 weeks]
• [18F]PI-2620PET SUVr regional uptake (occipital cortex, medial parietal/posterior cingulate cortex, temporoparietal cortex, medial temporal lobe, frontal lobes).
Secondary Outcome Measures
- MRI cortical volume [8 weeks]
MRI cortical volume
- MRI cortical thickness [8 weeks]
MRI cortical thickness
Other Outcome Measures
- Neurocognitive test results [8 weeks]
To determine the effects of OUD and non-fatal opioid OD on episodic memory performance. While in the MRI scanner, all participants will undergo a hippocampus-dependent visual episodic memory task during a functional MRI scan, for which hippocampal BOLD responses correlate with entorhinal [18F]PI-2620 binding in Alzheimer's disease.
Eligibility Criteria
Criteria
Inclusion Criteria:
OUD OD- group:
-
18-60 years-old
-
Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
-
Participants are in current treatment for OUD, which must include being on a stable dose of medication for at least 30 days prior to the screening visit.
-
Opioids are specified by the participant as their preferred drug
-
No lifetime history of OD per self-report or medical record review.
OUD OD+ group:
-
18-60 years-old
-
Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
-
Participants are in current treatment for OUD, which must include being on a stable dose of medication for at least 30 days prior to the screening visit.
-
Opioids are specified by the participant as their preferred drug
-
A history of at least 1 opioid OD that required naloxone reversal that occurred 1-12 months prior to study enrollment, as per self-report and/or medical record review.
Healthy Control (HC) group:
-
18-60 years-old 5. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
-
Must have never met lifetime history for Opioid Use Disorder (as per DSM-5) and not used an opioid for any reason in the 30 days prior to screening by self-report, medical record review, and urine drug testing at screening.
Exclusion Criteria:
-
HIV infection confirmed by an on-site rapid HIV test at screening. HIV affect neurocognitive function, even in otherwise asymptomatic individuals, which can confound the results of MRI testing.
-
Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed for women of child-bearing potential at the screening visit and on the days of the MRI and PET/CT scan visits.
-
At screening, the participant's weight is >350 lb. 17. Self-reported claustrophobia, which in the opinion of an investigator would interfere with acquisition of the structural MRI required for PET co-registration, and/or the PET scan itself.
-
Contraindications to MRI (e.g., metal in the body that cannot be removed and is not MRI compatible). An MRI screening form will be completed during screening to identify contraindications.
-
Screening lab values that indicate significant organ dysfunction that in the opinion of an investigator could compromise participant safety or successful participation in the study.
-
History of epilepsy or seizure disorder (that are not a result of substance use or substance withdrawal) as assessed by medical record review or self-report.
-
History of head trauma that in the opinion of an investigator may interfere with the uptake of applicable radiotracer as assessed by medical record review or self-report.
-
Current serious psychiatric disorder (bipolar disorder, schizophrenia, psychotic disorder, eating disorder, or major depression with suicidal ideation or psychotic features) identified by clinical examination or the structured psychiatric interview that could interfere with study participation or make it hazardous for the participant or staff to perform study procedures.
-
Self-reported heavy daily use of psychoactive substances in the past 30 days (prior to the screening visit), such as stimulants, cocaine, but not including nicotine, caffeine, cannabis (or opioids in the OUD groups) that could interfere with study performance.
-
Not able to provide a breath alcohol level of 0.000 (tested with handheld breath analyzer) at the scan study visit.
-
Inability to tolerate imaging procedures as determined by an investigator or treating physician 26. Any current medical condition, illness, or disorder assessed by medical record review and/or self-report that is considered by a physician or investigator to potentially compromise participant safety or their successful participation in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- University of Pennsylvania
- Yale University
Investigators
- Principal Investigator: Ilya Nasrallah, MD, PhD, Univeristy of Pennsylvania
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 852095